There were 2,238 press releases posted in the last 24 hours and 431,752 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image